search
Back to results

Short-term Antibiotic Therapy for Pyelonephritis in Childhood (STUTI)

Primary Purpose

Pyelonephritis

Status
Terminated
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
ceftibuten
ceftibuten
Sponsored by
IRCCS Burlo Garofolo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pyelonephritis focused on measuring Pyelonephritis., Urinary Tract Infections., Children., Randomised controlled trial., Therapy., Ceftibuten.

Eligibility Criteria

1 Month - 5 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 1 month to 5 years, with a first episode of pyelonephritis.

Exclusion Criteria:

  • Children less than 1 month, or older than 5 years.
  • Relapse of pyelonephritis.
  • Sepsis and/or vomiting, or other conditions where it's impossible to administer an oral therapy.
  • Allergy to ceftibuten.
  • Previous antibiotic therapy for the same infection.
  • Long term antibiotic prophylaxis with an antibiotic of the same class, if laboratory antibiotic resistance is shown.
  • Children with uncontrolled other disease.
  • Complicated pyelonephritis (abscess).

Sites / Locations

  • Institute for Child Health Burlo Garofolo

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Rate of renal SCAR

Secondary Outcome Measures

Relapses
Adverse effects of drug therapy

Full Information

First Posted
July 18, 2008
Last Updated
February 15, 2012
Sponsor
IRCCS Burlo Garofolo
search

1. Study Identification

Unique Protocol Identification Number
NCT00724256
Brief Title
Short-term Antibiotic Therapy for Pyelonephritis in Childhood
Acronym
STUTI
Official Title
Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Terminated
Why Stopped
other upcoming studies; patients refusal of invasive follow up (DMSA)
Study Start Date
July 2006 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS Burlo Garofolo

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy of oral ceftibuten for 7 days versus 10 days in acute pyelonephritis in children. The main hypothesis is that the ceftibuten for 7 days will be not inferior to ceftibuten 10 days in the rate of renal scarring at 6-12 months.
Detailed Description
Acute pyelonephritis is one of the most common serious bacterial infections in childhood, particularly in young children, with an estimated prevalence in febrile infants of 5.3%. It has been considered an important risk factor for the development of renal scarring, and renal insufficiency. More recently the long term outcomes of pyelonephritis has ameliorated, probably because of prompt diagnosis and therapy, and the importance of urinary tract infection as a risk factor for renal insufficiency has been questioned. Nevertheless, the optimal type and duration of antibiotic therapy for acute uncomplicated pyelonephritis in children is not established yet. There is a general agreement that children who are dehydrated, unable to drink, or in whom sepsis is possible, should be admitted to hospital for intravenous antibiotic treatment. Outside this conditions, evidence suggest that children with acute pyelonephritis can be treated effectively with cefixime, ceftibuten or amoxycillin/clavulanic acid. given orally (1). A recently updated Cochrane review on antibiotic treatment for acute pyelonephritis in children identified twenty three studies (3407 children). No significant differences were found in persistent renal damage at six to 12 months (824 children: RR 0.80, 95% CI 0.50 to 1.26) or in duration of fever (808 children: WMD 2.05, 95% CI -0.84 to 4.94) between oral antibiotic therapy (10 to 14 days) and IV therapy (3 days) followed by oral therapy (10 days). Similarly no significant differences in persistent renal damage (3 studies, 341 children: RR 1.13, 95% CI 0.86 to 1.49) were found between IV therapy (3 to 4 days) followed by oral therapy and IV therapy for 7 to 14 days. Authors concluded that children with acute pyelonephritis can be treated effectively with oral antibiotics (cefixime, ceftibuten and amoxycillin/clavulanic acid) or with short courses (2 to 4 days) of IV therapy followed by oral therapy. Oral treatment also is easier to use and does not require admission to hospital, leading to reduced costs. Nevertheless, the exact duration of oral therapy is not established. Current guidelines recommend 7-14 days course of broad-spectrum antibiotics capable of reaching significant renal levels. The objective of our study is to evaluate if oral ceftibuten for 7 days is equally effective as oral ceftibuten for 10 days in acute pyelonephritis in children. This is a non-inferiority randomised controlled trial to determine whether a short term therapy with ceftibuten ( 7 days) will be therapeutically similar to a long term therapy ( 10 days), measuring as major outcome the prevalence of renal scars.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pyelonephritis
Keywords
Pyelonephritis., Urinary Tract Infections., Children., Randomised controlled trial., Therapy., Ceftibuten.

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
ceftibuten
Intervention Description
ceftibuten 9mg/kg once a day for 7 days.
Intervention Type
Drug
Intervention Name(s)
ceftibuten
Intervention Description
ceftibuten 9mg/kg once a day for 10 days.
Primary Outcome Measure Information:
Title
Rate of renal SCAR
Time Frame
6-12 month from urinary tract infection
Secondary Outcome Measure Information:
Title
Relapses
Time Frame
up to12 months
Title
Adverse effects of drug therapy
Time Frame
10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 1 month to 5 years, with a first episode of pyelonephritis. Exclusion Criteria: Children less than 1 month, or older than 5 years. Relapse of pyelonephritis. Sepsis and/or vomiting, or other conditions where it's impossible to administer an oral therapy. Allergy to ceftibuten. Previous antibiotic therapy for the same infection. Long term antibiotic prophylaxis with an antibiotic of the same class, if laboratory antibiotic resistance is shown. Children with uncontrolled other disease. Complicated pyelonephritis (abscess).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marzia Lazzerini, MD DTMH
Organizational Affiliation
IRCCS Burlo Garofolo
Official's Role
Study Director
Facility Information:
Facility Name
Institute for Child Health Burlo Garofolo
City
Triest
ZIP/Postal Code
34137
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
17943796
Citation
Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003772. doi: 10.1002/14651858.CD003772.pub3.
Results Reference
background

Learn more about this trial

Short-term Antibiotic Therapy for Pyelonephritis in Childhood

We'll reach out to this number within 24 hrs